- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PR negative
- ER negative
- EGFR positive
- PD-L1 negative
- BRAF positive
- KRAS positive
- EGFR negative
- p16 positive
- BRCA1 positive
- HLA-A positive
- ALK negative
- CD20 positive
- BRCA2 positive
- ALK positive
- IDH positive
- CD19 positive
- MET positive
- HLA positive
- BRAF negative
- p16 negative
- HLA negative
- MYC positive
- IDH negative
- MSI-H positive
- ROS1 negative
- ROS1 positive
- MET negative
- RB1 positive
- TP53 positive
- HLA-A negative
- HPV positive
- PALB2 positive
- NRAS positive
- PIK3CA positive
- RB1 negative
- RET positive
- dMMR positive
- HR positive
- FLT3 positive
- HPV negative
- BCL2 positive
- BRCA positive
- KRAS negative
- NF1 positive
- RAS positive
- BCL6 positive
- CCND1 positive
- MSS positive
- ATM positive
- BCR-ABL1 positive
- MGMT negative
- MMR positive
- MSH2 positive
- NTRK positive
- PTEN positive
- ANA positive
- ARID1A positive
- BRCA1 negative
- CD30 positive
- CD5 positive
- HbSS positive
- MLH1 positive
- MSH6 positive
- PMS2 positive
- RET negative
- TP53 negative
- BRCA2 negative
- MMR negative
- PD-1 positive
- Philadelphia chromosome positive
- BRIP1 positive
- CHEK2 positive
- KIT positive
- MGMT positive
- MSI negative
- RAD51 positive
- RAS negative
- ctDNA positive
- dMMR negative
- p53 positive
- CD22 positive
- FGFR2 positive
- NRAS negative
- anti-dsDNA positive
- CDK12 positive
- FLT3 negative
- MSI positive
- MSI-H negative
- PD-1 negative
- FANCA positive
- L858R positive
- NTRK negative
- RAD51C positive
- BRCA negative
- CD19 negative
- CD4 positive
- Ex19del positive
- HBV DNA negative
- HRAS positive
- JAK2 positive
- NF2 positive
- RAD51D positive
- del(17p) positive
- pMMR positive
- t(11;14) positive
- BARD1 positive
- BCR-ABL positive
- CFTR positive
- CLDN18.2 positive
- HBsAg positive
- HPV16 positive
- HRD positive
- NPM1 positive
- NTRK1 positive
- SMN1 positive
- TERT positive
- APC positive
- ASXL1 positive
- BAP1 positive
- CD123 positive
- CD20 negative
- CD3 positive
- CD33 positive
- COL7A1 positive
- FGFR positive
- FGFR3 positive
- HBV DNA positive
- HBsAg negative
- HR negative
- Ki-67 positive
- MDM2 positive
- MSS negative
- NBN positive
- RF positive
- SMARCB1 positive
- complex karyotype positive
- t(9;22) positive
- ABCA4 positive
- AR positive
- ATR positive
- CD4 count positive
- CD8 positive
- CDK4 positive
- CHEK1 positive
- DLL3 positive
- EBV positive
- EPCAM positive
- FANCL positive
- FMR1 positive
- GPC3 positive
- GRN positive
- HBB positive
- HBcAb positive
- HbSC positive
- KMT2A positive
- MRE11 positive
- MSH6 negative
- PDGFRA positive
- PMS2 negative
- PTEN negative
- Ph positive
- Philadelphia chromosome negative
- RAF positive
- RB positive
- RUNX1 positive
- SMARCB1 negative
- SMN2 positive
- T790M positive
- TMB positive
- TROP2 positive
- TTR positive
- anti-Smith positive
- t(11;14)(q13;q32) positive
- AKT1 positive
- APOL1 positive
- CCND1 negative
- CD23 positive
- CDK6 positive
- CTNNB1 positive
- DMD positive
- EBV DNA positive
- ER or PR positive
- EZH2 positive
- FANCD2 positive
- FRα positive
- G719X positive
- HBcAb negative
- HbSβ0-thalassemia positive
- IA-2A positive
- ICA positive
- IGHV positive
- Ki67 positive
- L861Q positive
- MECP2 positive
- MLH1 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 2 Episodes of Recurrent Clostridium Difficile Infection
- 2 or More Previous Chemotherapies
- >= 2 Bone Metastases (Untreated Lesion)
- ALK TKI Therapy
- ANC >= 1,500/mcL
- ARD-101
- AST/ALT =< 3 x ULN
- ATG
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
12702 trials
1
2
3
…50